Elinzanetant与其他非激素药物治疗绝经中重度血管舒缩症状的疗效比较:网络Meta分析
本研究通过系统综述与贝叶斯网络Meta分析,间接比较Elinzanetant与其他非激素药物对绝经中重度血管舒缩症状的疗效。纳入17项RCT,结果显示Elinzanetant在减少VMS频率方面优于帕罗西汀、去甲文拉法辛和加巴喷丁,在改善睡眠障碍方面优于非唑奈坦,且耐受性良好。
要点
- Elinzanetant减少VMS频率优于帕罗西汀、去甲文拉法辛和加巴喷丁。
- Elinzanetant改善睡眠障碍优于非唑奈坦,夜间觉醒改善优于帕罗西汀和去甲文拉法辛。
- Elinzanetant在VMS严重程度和生活质量方面与其他非激素药物相当。
核心结论
- 在间接比较中,Elinzanetant在减少VMS频率和严重程度以及改善睡眠障碍方面显示出优于或相当于其他非激素药物的疗效。
研究设计与样本
- 系统综述与贝叶斯网络Meta分析,纳入17项随机对照试验,评估Elinzanetant 120 mg、帕罗西汀7.5 mg、加巴喷丁1200-1800 mg、非唑奈坦45 mg和去甲文拉法辛50-200 mg。
主要发现
- Elinzanetant显著降低每日VMS频率 vs 帕罗西汀(MD: -2.11 [-3.31, -0.92])、去甲文拉法辛(MD: -2.77至-1.72)和加巴喷丁(MD: -2.22至-2.31)。
- VMS频率降低≥50%的患者比例,Elinzanetant显著高于去甲文拉法辛100 mg(OR:1.52 [1.03, 2.24])和帕罗西汀(OR:2.20 [1.49, 3.28]),与非唑奈坦和去甲文拉法辛150 mg相当。
- Elinzanetant显著降低VMS严重程度 vs 去甲文拉法辛50 mg(MD: -0.37 [-0.56, -0.17]),与其他治疗相当。
- Elinzanetant减少夜间觉醒优于帕罗西汀(MD: -0.82 [-1.26, -0.39])和所有去甲文拉法辛方案。
- Elinzanetant改善睡眠障碍(PROMIS SD-SF-8b)评分优于非唑奈坦(MD: -2.67 [-3.92, -1.42]),MENQoL变化无显著差异。
临床怎么用
- 对于不能或不愿使用激素疗法的绝经中重度VMS女性,Elinzanetant可作为有效非激素选择,尤其适用于关注VMS频率和睡眠改善者。
局限性
- 结果为间接比较,需谨慎解读,不能替代直接头对头临床试验。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Elinzanetant, a novel, dual neurokinin-targeted therapy, has been approved in various geographies for the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause. OBJECTIVE: To compare the efficacy of elinzanetant with non-hormonal pharmaceutical treatments (nHT) in alleviating VMS. SEARCH STRATEGY: A systematic literature review of Medline, Embase, and Cochrane databases identified randomised controlled trials (RCTs) published up to October 2025. SELECTION CRITERIA: RCTs of nHT in women with moderate-to-severe VMS not induced by medical treatment, reporting week 12 results for VMS frequency and severity, sleep disturbances, and quality of life. DATA COLLECTION AND ANALYSIS: Treatments were compared using a Bayesian network meta-analysis to obtain mean differences (MD) or odds ratios (OR) with 95% credible intervals. MAIN RESULTS: Of 17 included RCTs, three assessed elinzanetant 120 mg, two paroxetine 7.5 mg (PRX), four gabapentin 1200-1800 mg (GABA), three fezolinetant 45 mg (FEZO), and five desvenlafaxine 50-200 mg (DVS). Elinzanetant significantly reduced daily VMS frequency versus PRX (MD: -2.11 [-3.31, -0.92]), DVS (MD: -2.77 to -1.72), and GABA (MD: -2.22 to -2.31). The proportion of patients with ≥ 50% reduction in VMS frequency was significantly greater with elinzanetant than DVS 100 mg (OR:1.52 [1.03, 2.24]) and PRX (OR:2.20 [1.49, 3.28]), and comparable to DVS 150 mg and FEZO. Elinzanetant significantly reduced VMS severity versus DVS 50 mg (MD: -0.37 [-0.56, -0.17]) and was comparable with other assessed treatments. Elinzanetant reduced nighttime awakenings significantly more effectively than PRX (MD: -0.82 [-1.26, -0.39]) and all DVS regimens. Elinzanetant significantly improved sleep disturbance (PROMIS SD-SF-8b) score versus FEZO (MD: -2.67 [-3.92, -1.42]). Change in MENQoL did not differ significantly. CONCLUSIONS: In this indirect comparison, elinzanetant showed superior or comparable efficacy to NKT or nHT in reducing the frequency and severity of VMS, along with improving sleep disturbances, supporting its role in VMS management. BACKGROUND: Many women experience disruptive symptoms during menopause. Some of the most frequent symptoms include vasomotor symptoms and sleep disturbances, and both can impact women's quality of life. Hormone therapies have been used to treat these symptoms, but they can have side effects, and some women are either not able to or do not wish to be treated with hormone therapies. Non‐hormonal therapies, such as the recent neurokinin‐targeted therapies, are options for women who cannot or do not want to use hormone therapies. OBJECTIVE: The objective of this study was to indirectly compare the efficacy of a new neurokinin‐targeted therapy, called elinzanetant, with non‐hormonal therapies in reducing menopausal symptoms such as hot flashes and improving sleep disturbances. METHODS: This analysis includes data from 17 clinical trials that evaluated various non‐hormonal treatments for menopausal symptoms. Each trial compared a treatment to placebo. To assess and compare the effectiveness of these treatments, researchers used a method called network meta‐analysis. This statistical technique allows for indirect comparisons between treatments, even when they haven't been directly tested against each other in the same clinical trial. While network meta‐analysis does not replace direct head‐to‐head clinical trials, it can provide useful insights for decision‐makers, such as healthcare payers. In this analysis, results were considered statistically significant if the 95% credible interval did not include the null value. The non‐hormonal therapies examined in this study have all demonstrated some effectiveness in managing menopause symptoms such as hot flashes. These therapies include desvenlafaxine (a serotonin‐norepinephrine reuptake inhibitor) and paroxetine (a selective serotonin reuptake inhibitor), which are antidepressants; gabapentin, an anticonvulsant; and fezolinetant, a recently approved neurokinin‐targeted therapy. Among these, only fezolinetant and paroxetine have been specifically approved for the treatment of vasomotor symptoms associated with menopause. Notably, paroxetine has received this approval only in the United States. RESULTS: Elinzanetant was found to be more effective than desvenlafaxine, gabapentin, and paroxetine in reducing the frequency of hot flashes. It also improved sleep disturbances better than other treatments, including fezolinetant. Elinzanetant was found to be comparable with gabapentin and fezolinetant in improving quality of life. These results should be interpreted in the context of estimates being derived from an indirect comparison. CONCLUSION: Elinzanetant appears to be a promising additional treatment option for reducing menopausal symptoms, namely hot flashes and sleep disturbances, based on results of this indirect comparison.
引用
- Wojciechowski P, Kolonko K, Giannopoulou A, et al. Comparative Efficacy of Elinzanetant Versus Other Non-Hormonal Pharmaceutical Therapies for the Treatment of Moderate-to-Severe Vasomotor Symptoms Associated With Menopause: A Network Meta-Analysis. BJOG. 2026. PMID: 41834312. doi:10.1111/1471-0528.70213
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。